ATRC (AtriCure, Inc.) — Stock Analysis, Catalysts & AI Research

AtriCure, Inc.

$28.59

Health CareMedical - Instruments & Supplies

The Read: ATRC’s stock sharply declined about 14% after Q4 2025 guidance disappointed on profitability and growth, then dropped about 22% as ablation product adoption lagged expectations, while Q1 2026 earnings beat estimates but failed to spark gains.

Price

Overlays

Panel

ATRC

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

AtriCure, Inc.

$28.59

Health CareMedical - Instruments & Supplies

Price

Overlays

Panel

ATRC

Hover to view data

No Data

The Stats

Market Cap

N/A

Total outstanding shares value

Earnings Per Share (EPS)

N/A

Latest reported

Net Profit Margin

N/A

Net Income / Revenue

Revenue Growth (YoY)

N/A

Prior year same period

Debt / Equity

N/A

Leverage risk indicator

Dividend Yield

0.00%

Annualized Return

Free Cash Flow

N/A

No data

Create your free account to unlock active Expected Moves for ATRC

Expected Moves

AtriCure, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow

Create your free account to unlock active Expected Moves for ATRC

Expected Moves

AtriCure, Inc.

The Stats

Market Cap

Earnings Per Share (EPS)

Net Profit Margin

Revenue Growth (YoY)

Debt / Equity

Dividend Yield

Free Cash Flow